Endocrine Abstracts

Adjuvant treatment for post-menopausal women with early breast cancer (BC) includes aromatase inhibitors (AI), known to decrease bone mineral density (BMD). In this study, we investigate whether denosumab is a valid second option for patients unable to receive standard adjuvant i.v. zoledronic acid (ZA). In total, 212 patients have been evaluated after they did not receive ZA. Of those 194 were included. After evaluation by an endocrinologist, all patients were offered ZA as t...

Objective: Adjuvant chemotherapy is often indicated in patients diagnosed with early breast cancer. Weight gain is one of the observed side effects of both chemotherapy and other cancer treatments, however, the mechanism is not well-described. In this study, we aimed to assess thyroid function before- and after the course of chemotherapy for early breast cancer.Methods: This study is a 5-year prospective cohort study of patients diagnosed with early brea...

Introduction: Aromatase inhibitors, such as Letrozole or Exemestane, are often used as adjuvant treatment for post-menopausal breast cancer. However, they are known to reduce bone mineral density (BMD). Furthermore, breast cancer patients often undergo chemotherapy with drugs associated to BMD loss by themselves. Therefore, patients treated for breast cancer are subject to a considerable risk of BMD loss, and to alleviate this the treatments are normally combined with an anti-...

Background: Breast cancer survivors are a growing population due to improved treatment. It is known that postmenopausal women treated for breast cancer may experience weight gain and increased insulin resistance, but detailed knowledge on how chemotherapy impact metabolic and endocrine mechanisms remain unknown. Objective: We performed a thorough, preliminary study to elucidate the differing mechanisms of post-prandial absorption and metabolism in postme...

Background: Observational studies indicate that breast cancer survivors more often are diagnosed with type 2 diabetes mellitus (T2DM) up to several years after treatment completion. As the population of breast cancer survivors increase due to improved diagnostic and treatment methods the importance of understanding possible long-term side effects of the treatment such as T2DM becomes more central. It is reported that women receiving adjuvant chemotherapy experience weight gain...

Background: Through the decades, aromatase inhibitor maintenance therapy for patients with postmenopausal non-metastatic estrogen receptor-positive breast cancer has improved significantly. This study focuses on the patient’s further breast cancer course and clarifies the extensive symptom burden that the endocrinologist should be aware of.Aim: The study aims to gain insight into a potential gap between the endocrine symptoms outlined in guidelines ...